What Does ER-Low Positive Mean in Invasive Ductal Carcinoma?

An ER-low positive result means that between 1% and 10% of the cancer cells in your tumor have estrogen receptors. In breast cancer, this creates a clinically important “gray area.” Because the tumor has some receptors, your doctors will likely discuss endocrine therapy (anti-estrogen treatments) as an option, as it may provide some benefit ^[1]. However, biologically, these tumors frequently grow and respond to treatments more like ER-negative cancers than cancers with higher ER expression ^[2].

It is important to know that treatments like surgery, chemotherapy, radiation, and endocrine therapy serve different purposes and are often combined. Choosing one does not necessarily mean avoiding the others.

The 1% to 10% “Gray Area” in Pathology

When a pathologist examines a biopsy, they stain the cells to see how many have estrogen receptors (ER). According to the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP), a tumor is considered ER-negative if less than 1% of cells stain positive. If 1% to 10% stain positive, it is officially classified as “ER-low positive” ^[1].

Because 1% to 10% is a very small amount, the result can sometimes be affected by the small biopsy sample or how the staining was done ^[1]. It is entirely appropriate to ask your doctor if the laboratory controls were reviewed to confirm the result. Your care team will also look at your Progesterone Receptor (PR) status; tumors that are ER-low but PR-positive may behave differently and have a different prognosis than those that are negative for both ^[3].

Endocrine (Anti-Estrogen) Therapy Options

Because the tumor has some estrogen receptors, endocrine therapy remains a consideration. Observational studies have associated endocrine therapy with better overall survival and a lower chance of the cancer returning in patients with ER-low tumors ^[4]. However, because this evidence comes from observing past patient data rather than randomized trials, the exact size of the benefit is uncertain. The absolute benefit is generally expected to be smaller than it is for patients with higher ER expression (where more than 10% of cells have receptors) ^[1][5].

Because the benefit is less certain, the decision to take endocrine therapy becomes highly personalized. You and your doctor will weigh the possible reduction in cancer recurrence against the specific side effects of the medication, which depend heavily on your menopausal status ^[6]:

• Tamoxifen: Often used for premenopausal patients. Side effects can include hot flashes, and less commonly, serious risks like blood clots or endometrial changes ^[6].
• Aromatase Inhibitors: Used for postmenopausal patients, or premenopausal patients who are also taking medication to suppress their ovaries. These are particularly associated with joint pain, stiffness, and bone density loss ^[7][8].

Chemotherapy and Immunotherapy Considerations

Because ER-low tumors often share genetic features with ER-negative tumors, they can be highly responsive to chemotherapy ^[2][9]. Studies show that when treated with neoadjuvant chemotherapy (chemotherapy given before surgery), some ER-low tumors shrink significantly, achieving rates of complete tumor clearance (pathologic complete response) comparable to triple-negative breast cancer ^[2][10]. While a strong early response is encouraging, it is not a guarantee of a cure, and chemotherapy is not prescribed based on the ER percentage alone.

If your ER-low tumor is also HER2-negative, it may act similarly to triple-negative breast cancer (TNBC), which is formally defined as having less than 1% ER and PR ^[10][11]. Some chemotherapy approaches may be planned using TNBC-like evidence. However, immunotherapy is not automatically recommended just because a tumor is ER-low. Immunotherapy requires separate, individualized eligibility (such as specific PD-L1 testing, or whether the cancer is early-stage vs. metastatic) and there is less direct clinical trial evidence specifically for the ER-low subgroup ^[12][13].

Your doctor’s recommendation for systemic treatment (medications that travel through the body) will be tailored to your specific risk factors, including:

• HER2 Status: If your tumor is HER2-positive, you will receive targeted anti-HER2 therapies alongside chemotherapy ^[14].
• Stage and Grade: Larger tumors, cancer that has spread to lymph nodes (higher stage), or faster-growing cells (higher grade) influence the overall recurrence risk and guide how intensive your treatment should be ^[14].
• Overall Health: Your personal medical history and goals.

An ER-low result means your care team will look closely at your entire pathology report to ensure your treatment plan is appropriate for the cancer’s features and your overall health.